BioSpace News Archive

In an unprecedented collaboration, premier microbiome CDMO List Labs partners with leading global clinical stage biotechnology company, Genome and Company.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the JP Morgan 12th Annual U.S. All Stars Conference on Wednesday, September 22, 2021 at 9:00 a.m. (EDT).

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik Atkisson as the Company’s General Counsel and Chief Compliance Officer.

Serimmune, a leader in understanding the antibody repertoire’s role in human disease, and Mymee, a leading provider of digital care programs for reducing persistent symptoms resulting from autoimmune disease, chronic inflammation and long haul COVID, announced today that they will collaborate on a clinical research study to describe the role antibodies play in patients suffering from COVID-19.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced the completion of enrollment in DESTINY-1 Efficacy and Safety Trial In NASH), a dose-ranging Phase 2 trial evaluating PXL065 for the treatment of NASH.

External counterpulsation is a non-invasive and medically proven treatment recommended for patients with angina or congestive heart failure condition.

Gingivostomatitis is a contagious mouth infection that causes blisters, painful sores, and swelling in the tongue and uvula. It usually spreads via saliva of an infected individual or by direct contact with a lesion or sore.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest Fact.MR analysis, the global hepatitis rapid testing market is forecast to register high growth between 2021 and 2031.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on Seneca Valley Virus, announced the launch of a novel Cancer Gene Delivery Platform based on SVV-001 technology.

Willow Biosciences Inc. is pleased to provide the following operational and corporate updates.